Drug intelligence / Profile preview

velinotamig

Development stage: Phase 3
Lead developer: Cullinan Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
Administration: Parenteral

Overview

Velinotamig is a recombinant humanized bispecific antibody that simultaneously binds to B-cell maturation antigen (BCMA) and CD3, functioning as a bispecific T cell engager (TCE). By targeting BCMA on tumor cells and CD3 on T lymphocytes, it redirects and stimulates cytotoxic T cells to eliminate BCMA-expressing cells. Velinotamig has shown significant efficacy in Phase 2 studies for relapsed/refractory multiple myeloma and is being investigated for autoimmune diseases. It was initially developed by Genrix (Shanghai) Biopharmaceuticals (also known as Chongqing Genrix BioPharmaceutical) and out-licensed ex-Greater China to Cullinan Therapeutics for worldwide development in various indications, including oncology and autoimmunity.

Other names: velinotamig

Targets

CD3 (T-cell surface glycoprotein CD3)BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on velinotamig.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on velinotamig.

Explore the full profile